Ghemaxan: Uses, Dosage & Side Effects
A low molecular weight heparin (enoxaparin sodium) for the prevention and treatment of venous thromboembolism, administered as a subcutaneous injection
Ghemaxan (enoxaparin sodium) is a prescription low molecular weight heparin (LMWH) used to prevent and treat blood clots. It belongs to the class of anticoagulant medications and works by enhancing the activity of antithrombin III, primarily inhibiting coagulation factor Xa to prevent thrombus formation. Ghemaxan is available as a pre-filled syringe containing 2,000 IU (20 mg) in 0.2 mL, administered by subcutaneous injection. It is commonly prescribed for the prevention of deep vein thrombosis (DVT) after surgical procedures, the treatment of existing DVT with or without pulmonary embolism, prevention of clotting during hemodialysis, and the management of acute coronary syndromes including unstable angina and non-ST-elevation myocardial infarction.
Quick Facts: Ghemaxan
Key Takeaways
- Ghemaxan (enoxaparin sodium) is a low molecular weight heparin used for the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, as well as for anticoagulation during hemodialysis and acute coronary syndromes.
- The medication is administered by subcutaneous injection into the abdominal wall using a convenient pre-filled syringe, and many patients can learn to self-inject at home after proper training from a healthcare professional.
- Unlike unfractionated heparin, enoxaparin has a more predictable dose-response relationship and generally does not require routine monitoring of coagulation parameters, although anti-Xa levels may be monitored in special populations such as patients with renal impairment or obesity.
- The most common side effects are bleeding and injection site reactions (bruising, pain, hematoma); serious but rare adverse effects include heparin-induced thrombocytopenia (HIT) and spinal/epidural hematoma in patients undergoing neuraxial anesthesia.
- Dose adjustment is required in patients with severe renal impairment (creatinine clearance below 30 mL/min), and platelet counts should be monitored regularly during treatment to detect heparin-induced thrombocytopenia early.
What Is Ghemaxan and What Is It Used For?
Ghemaxan contains the active substance enoxaparin sodium, which belongs to the pharmacological class of low molecular weight heparins (LMWHs). Enoxaparin is derived from unfractionated heparin (UFH) through a controlled depolymerization process that produces shorter polysaccharide chains with an average molecular weight of approximately 4,500 daltons (ranging from 3,800 to 5,000 daltons). This reduction in molecular weight gives enoxaparin distinct pharmacological advantages over traditional unfractionated heparin, including a more predictable anticoagulant response, improved subcutaneous bioavailability, a longer plasma half-life, and a reduced risk of heparin-induced thrombocytopenia (HIT).
The anticoagulant mechanism of enoxaparin centers on its interaction with antithrombin III (AT-III), a naturally occurring protease inhibitor in the blood. When enoxaparin binds to AT-III, it induces a conformational change that dramatically accelerates the rate at which AT-III inactivates several key serine proteases in the coagulation cascade. The most important of these is factor Xa, which occupies a central position in the common pathway of coagulation where the intrinsic and extrinsic pathways converge. By preferentially inhibiting factor Xa, enoxaparin effectively blocks the conversion of prothrombin to thrombin, thereby preventing fibrin formation and the subsequent development of blood clots. Enoxaparin also inhibits factor IIa (thrombin), though to a lesser extent, with an anti-Xa to anti-IIa ratio of approximately 3.8:1. This ratio is clinically significant because it means that enoxaparin provides potent anticoagulation while having a comparatively smaller effect on thrombin-dependent functions such as platelet aggregation and clot-bound thrombin activity.
After subcutaneous injection, enoxaparin is rapidly and almost completely absorbed, with a bioavailability approaching 100%. This is substantially higher than the subcutaneous bioavailability of unfractionated heparin, which is typically only 20–30%. Peak anti-factor Xa activity occurs approximately 3 to 5 hours after injection, and the elimination half-life of anti-Xa activity is approximately 4 to 5 hours after a single dose, extending to approximately 7 hours after repeated dosing. This pharmacokinetic profile supports once-daily or twice-daily dosing regimens, which are far more convenient than the continuous intravenous infusion required for unfractionated heparin. Enoxaparin is primarily eliminated through the kidneys, which is an important consideration for dose adjustment in patients with impaired renal function.
Ghemaxan is indicated for several clinical situations where prevention or treatment of thrombosis is required:
- Prevention of venous thromboembolism (VTE) in surgical patients: Ghemaxan is widely used for thromboprophylaxis in patients undergoing moderate- to high-risk surgical procedures, including orthopedic surgery (hip and knee replacement, hip fracture surgery), abdominal and pelvic surgery, and other procedures associated with an increased risk of DVT and pulmonary embolism (PE). Prophylactic treatment typically begins before or shortly after surgery and continues until the patient is fully mobile, usually 7 to 14 days.
- Prevention of VTE in medical patients: Patients hospitalized for acute medical illness who are at increased risk of VTE due to restricted mobility can benefit from enoxaparin prophylaxis. This includes patients with acute heart failure, severe respiratory disease, acute infection, or acute rheumatic disease.
- Treatment of deep vein thrombosis (DVT): Ghemaxan is used for the treatment of established DVT, with or without pulmonary embolism. Treatment-dose enoxaparin is typically administered for at least 5 days and until oral anticoagulation (such as warfarin or a direct oral anticoagulant) has reached therapeutic levels.
- Prevention of clot formation during hemodialysis: Enoxaparin can be administered into the arterial line of the dialysis circuit to prevent clot formation during extracorporeal hemodialysis sessions.
- Acute coronary syndromes: Ghemaxan is used in the management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), typically in combination with aspirin. It is also used in the treatment of acute ST-segment elevation myocardial infarction (STEMI), including patients managed with percutaneous coronary intervention (PCI) or thrombolytic therapy.
The efficacy of enoxaparin in these indications has been established through numerous large-scale randomized controlled trials. Landmark studies such as MEDENOX (Medical Patients with Enoxaparin), ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment), and multiple orthopedic surgery trials have consistently demonstrated that enoxaparin significantly reduces the incidence of venous thromboembolic events compared with placebo and is at least as effective as unfractionated heparin with a more favorable safety and convenience profile.
Low molecular weight heparins like enoxaparin have largely replaced unfractionated heparin for most indications because they offer several practical advantages: predictable dose-response (eliminating the need for routine coagulation monitoring), once- or twice-daily subcutaneous dosing (enabling outpatient treatment), higher bioavailability, lower risk of heparin-induced thrombocytopenia (HIT), and lower risk of osteoporosis with long-term use. These properties make LMWHs the preferred choice for thromboprophylaxis and treatment in most clinical guidelines worldwide.
What Should You Know Before Taking Ghemaxan?
Contraindications
There are several situations in which Ghemaxan must not be used. The most important contraindications include hypersensitivity (allergy) to enoxaparin sodium, heparin, or any of the other ingredients in the formulation. Because enoxaparin is derived from porcine intestinal mucosa, patients with a known allergy to pork or pork-derived products should not use this medication. Active clinically significant bleeding is an absolute contraindication, as anticoagulation would exacerbate hemorrhage. This includes active gastrointestinal bleeding, intracranial hemorrhage, and other conditions with ongoing major blood loss.
A history of confirmed heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies is also a contraindication. HIT is a serious immune-mediated condition in which antibodies against heparin-platelet factor 4 complexes activate platelets, paradoxically causing both thrombocytopenia and an increased risk of thrombosis. Patients with a history of HIT should be treated with alternative non-heparin anticoagulants such as argatroban, bivalirudin, or fondaparinux.
Other contraindications include conditions associated with a high risk of uncontrolled hemorrhage, such as active gastric or duodenal ulceration, hemorrhagic stroke within the recent past, severe uncontrolled hypertension, bacterial endocarditis, and recent brain, spinal, or ophthalmic surgery. Enoxaparin should not be used for treatment (as opposed to prophylaxis) of VTE in patients with prosthetic heart valves, as the efficacy and safety in this specific population have not been adequately studied.
Warnings and Precautions
Patients receiving enoxaparin who undergo spinal or epidural anesthesia or spinal puncture are at risk of developing spinal or epidural hematoma, which can result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters, concomitant use of other drugs affecting hemostasis (NSAIDs, platelet inhibitors, other anticoagulants), a history of traumatic or repeated epidural or spinal puncture, or a history of spinal deformity or surgery. Patients should be monitored frequently for signs of neurological impairment, and urgent treatment is necessary if spinal cord compression is suspected.
Several important warnings and precautions apply to the use of Ghemaxan. Enoxaparin, like all anticoagulants, carries a risk of hemorrhage. Bleeding can occur at any site and can range from minor (such as injection site bruising) to major and potentially life-threatening (such as intracranial, retroperitoneal, or gastrointestinal hemorrhage). Risk factors for bleeding include advanced age, renal impairment, low body weight (less than 45 kg), concurrent use of medications that affect hemostasis, and conditions associated with increased bleeding risk. Any unexplained fall in hemoglobin or blood pressure should be investigated promptly as it may indicate occult bleeding.
Heparin-induced thrombocytopenia (HIT) can occur with any heparin product, including LMWHs. Platelet counts should be measured before initiation of treatment and monitored regularly throughout therapy. A significant decrease in platelet count (30–50% decline from baseline) should trigger further investigation for HIT. If HIT is confirmed, enoxaparin must be discontinued immediately and an alternative non-heparin anticoagulant initiated.
Patients with severe renal impairment (creatinine clearance less than 30 mL/min) have reduced clearance of enoxaparin, leading to increased drug exposure and a higher risk of bleeding complications. Dose reduction is recommended in these patients. Regular monitoring of anti-Xa levels may be considered to guide dosing. Mild to moderate renal impairment does not generally require dose adjustment, although clinical vigilance is warranted.
Enoxaparin should be used with caution in patients with low body weight. Women weighing less than 45 kg and men weighing less than 57 kg have increased exposure to prophylactic doses of enoxaparin, and monitoring may be appropriate. Obese patients may also require dose adjustment or monitoring, as standard fixed-dose prophylaxis may be subtherapeutic in patients with very high body weight.
Pregnancy and Breastfeeding
Enoxaparin sodium does not cross the placenta in significant amounts, which is a major advantage over oral anticoagulants such as warfarin (which is teratogenic and contraindicated in early pregnancy). For this reason, LMWHs including enoxaparin are considered the anticoagulants of choice during pregnancy when anticoagulation is clinically indicated. Common indications for enoxaparin use during pregnancy include prevention and treatment of venous thromboembolism, thromboprophylaxis in women with thrombophilia or prior VTE, prevention of pregnancy loss in women with antiphospholipid syndrome, and anticoagulation in women with mechanical heart valves (although this last indication requires very careful specialist management).
Despite the favorable safety profile, pregnant women receiving enoxaparin should be closely monitored by both an obstetrician and a hematologist. Anti-Xa levels may be monitored to ensure therapeutic or prophylactic levels are maintained, as the pharmacokinetics of enoxaparin can change during pregnancy due to increased renal clearance and volume of distribution. Enoxaparin must be discontinued before labor and delivery or before epidural or spinal anesthesia to minimize bleeding risk. Specific timing protocols (typically discontinuation 12 hours before for prophylactic doses or 24 hours before for treatment doses) should be discussed with your healthcare team.
Limited data suggest that enoxaparin is excreted in breast milk in very small quantities, and the oral bioavailability of heparin is negligible. Therefore, enoxaparin is generally considered compatible with breastfeeding. However, as a precaution, discuss breastfeeding with your doctor if you are taking Ghemaxan.
Children and Adolescents
The safety and efficacy of enoxaparin in children and adolescents have not been established through large randomized controlled trials to the same extent as in adults. However, enoxaparin is widely used off-label in pediatric patients for the treatment and prevention of thromboembolism, with dosing adjusted according to body weight and guided by anti-Xa monitoring. Pediatric dosing typically starts higher than adult doses on a per-kilogram basis because children have faster clearance. All pediatric use should be supervised by a specialist experienced in pediatric anticoagulation.
How Does Ghemaxan Interact with Other Drugs?
The primary concern with drug interactions involving enoxaparin is the additive or synergistic increase in bleeding risk when combined with other agents that affect hemostasis. Unlike many oral medications, enoxaparin does not undergo hepatic metabolism through cytochrome P450 (CYP) enzymes, so traditional pharmacokinetic drug interactions are not a significant concern. Instead, the relevant interactions are pharmacodynamic in nature, meaning they relate to the combined effects of multiple agents on the blood clotting process.
Healthcare providers should be informed about all medications, supplements, and herbal products you are using before starting Ghemaxan. The following table summarizes the most clinically important drug interactions:
| Drug / Drug Class | Interaction Type | Clinical Significance |
|---|---|---|
| Aspirin (acetylsalicylic acid) | Increased bleeding risk | Major – May be intentionally co-prescribed in ACS but requires close monitoring |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Increased bleeding risk, impaired platelet function | Major – Avoid combination when possible; if necessary, monitor closely |
| Warfarin and other vitamin K antagonists | Additive anticoagulant effect | Major – Overlap is common during transition; monitor INR closely |
| DOACs (rivaroxaban, apixaban, edoxaban, dabigatran) | Additive anticoagulant effect | Major – Concomitant use generally not recommended; switch protocols should minimize overlap |
| Clopidogrel, ticagrelor, prasugrel | Increased bleeding risk, impaired platelet aggregation | Major – Combination used in ACS; requires careful bleeding risk assessment |
| Thrombolytics (alteplase, streptokinase, tenecteplase) | Greatly increased bleeding risk | Major – Used together in STEMI protocols under specialist supervision only |
| Dextran 40 or Dextran 70 | Increased bleeding risk, impaired platelet function | Moderate – Avoid combination if possible |
| Systemic corticosteroids | Increased gastrointestinal bleeding risk | Moderate – Monitor for GI bleeding symptoms |
| SSRIs and SNRIs | Impaired platelet function, increased bleeding risk | Moderate – Be aware of increased bruising and bleeding tendency |
Major Interactions
The most clinically significant interactions occur when enoxaparin is combined with other anticoagulants, antiplatelet agents, or thrombolytic drugs. The combination of enoxaparin with aspirin is intentionally used in acute coronary syndromes (unstable angina, NSTEMI, and STEMI), where the complementary mechanisms of anticoagulation and platelet inhibition provide superior outcomes. However, this combination significantly increases bleeding risk and requires careful assessment of the benefit-risk balance for each individual patient. Similarly, dual or triple antithrombotic therapy (enoxaparin plus aspirin plus clopidogrel or ticagrelor) is used in specific clinical scenarios but demands heightened vigilance for bleeding complications.
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and diclofenac should be avoided whenever possible during enoxaparin therapy. NSAIDs impair platelet function by inhibiting cyclooxygenase (COX) enzymes and also increase the risk of gastrointestinal bleeding. If analgesia is required during enoxaparin treatment, paracetamol (acetaminophen) is generally the preferred first-line option, as it does not significantly affect platelet function or bleeding risk.
Minor Interactions
Herbal supplements such as ginkgo biloba, garlic supplements, ginger, and fish oil (omega-3 fatty acids) may have mild antiplatelet or anticoagulant effects and could theoretically increase bleeding risk when combined with enoxaparin. While these interactions are generally considered minor, patients should inform their healthcare provider about all supplements they are taking. Vitamin E in high doses may also have a mild anticoagulant effect.
Certain antibiotics, particularly those that significantly alter gut flora (such as broad-spectrum antibiotics), may affect vitamin K metabolism and potentially enhance the anticoagulant effects of concomitant warfarin therapy during the transition period from enoxaparin to oral anticoagulation. This is an indirect interaction but is worth noting in the context of overall anticoagulation management.
In cases of serious overdose or life-threatening bleeding, protamine sulfate can be used to partially neutralize the anticoagulant effect of enoxaparin. Protamine completely neutralizes the anti-IIa (antithrombin) activity of enoxaparin but only partially neutralizes the anti-Xa activity (approximately 60%). The recommended dose is 1 mg of protamine sulfate per 1 mg (100 IU) of enoxaparin administered within the preceding 8 hours. If bleeding continues, a second dose of 0.5 mg protamine per 1 mg of enoxaparin may be given. Always seek emergency medical attention for suspected enoxaparin overdose.
What Is the Correct Dosage of Ghemaxan?
Ghemaxan should always be used exactly as prescribed by your doctor. The dosage of enoxaparin varies significantly depending on the clinical indication, and it is essential that the correct dose is administered for each specific situation. The medication is injected subcutaneously (under the skin) into the abdominal wall. Do not inject Ghemaxan intramuscularly. The pre-filled syringe makes accurate dosing straightforward, but always check the syringe markings and verify you are using the correct strength before each injection.
Adults
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| Surgical prophylaxis (moderate risk) | 20 mg (2,000 IU) | Once daily | 7–10 days or until mobile |
| Surgical prophylaxis (high risk, e.g., orthopedic) | 40 mg (4,000 IU) | Once daily | Up to 5 weeks post-surgery |
| Medical prophylaxis (acutely ill) | 40 mg (4,000 IU) | Once daily | 6–14 days |
| DVT treatment | 1 mg/kg or 1.5 mg/kg | Twice daily or once daily | ≥5 days + until oral anticoagulation therapeutic |
| Unstable angina / NSTEMI | 1 mg/kg | Twice daily | 2–8 days (with aspirin) |
| STEMI (with thrombolysis) | 30 mg IV bolus + 1 mg/kg SC | SC dose twice daily | Up to 8 days or until discharge |
| Hemodialysis | 1 mg/kg into arterial line | Per dialysis session | Duration of session (max 4 hours) |
For surgical thromboprophylaxis, the first injection is typically given 2 hours before surgery (for moderate-risk procedures) or 12 hours before surgery (for high-risk orthopedic procedures). In orthopedic surgery, extended prophylaxis for up to 5 weeks after surgery has been shown to further reduce the risk of VTE, particularly after hip replacement surgery. Your surgeon or hospital team will determine the appropriate timing and duration based on your individual risk factors.
For DVT treatment, there are two dosing options: 1 mg/kg administered twice daily (every 12 hours) or 1.5 mg/kg administered once daily. Both regimens have demonstrated equivalent efficacy in clinical trials. The twice-daily regimen is generally preferred in patients with cancer-associated thrombosis, pulmonary embolism, or those at higher risk of recurrence, while the once-daily regimen may be preferred for its convenience in outpatient management. Treatment is continued for at least 5 days and until oral anticoagulant therapy (typically warfarin with a target INR of 2.0–3.0, or a direct oral anticoagulant) has reached therapeutic levels on two consecutive measurements at least 24 hours apart.
Elderly Patients
No dose adjustment is generally required for elderly patients with normal renal function. However, elderly patients are at increased risk of both thromboembolism and bleeding complications, so careful monitoring is essential. Renal function should be assessed before starting treatment, as age-related decline in kidney function is common and may necessitate dose reduction. For patients aged 75 years and older being treated for STEMI, the initial IV bolus is omitted, and the subcutaneous dose is reduced to 0.75 mg/kg twice daily (maximum 75 mg per dose for the first two doses).
Renal Impairment
Dose Adjustment for Severe Renal Impairment (CrCl < 30 mL/min)
Patients with severe renal impairment require dose reduction due to decreased clearance of enoxaparin:
- Prophylactic dose: Reduce from 40 mg to 20 mg once daily
- Treatment dose (DVT/PE): Reduce from 1 mg/kg twice daily to 1 mg/kg once daily
- ACS treatment: Reduce from 1 mg/kg twice daily to 1 mg/kg once daily
Monitoring of anti-Xa levels is recommended in patients with severe renal impairment to ensure appropriate anticoagulation without excessive drug accumulation.
Missed Dose
If you miss a dose of Ghemaxan, take it as soon as you remember unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not inject a double dose to compensate for a missed one. If you are unsure about what to do, contact your doctor or pharmacist for guidance. Maintaining consistent dosing is important for effective anticoagulation, and missed doses can increase the risk of thromboembolism.
Overdose
Accidental overdose of enoxaparin by the subcutaneous or intravenous route may lead to hemorrhagic complications. The severity of bleeding depends on the degree of overdose and the patient’s individual risk factors. Minor overdoses in patients without additional bleeding risk factors may require only clinical observation and monitoring. Significant overdoses or those associated with active bleeding should be treated with protamine sulfate, the partial antidote for enoxaparin. As protamine only partially reverses the anti-Xa activity of enoxaparin (approximately 60% neutralization), supportive measures including blood transfusion and surgical hemostasis may also be necessary. If you suspect an overdose, contact emergency medical services immediately.
What Are the Side Effects of Ghemaxan?
Like all medicines, Ghemaxan can cause side effects, although not everybody experiences them. The most important side effect to be aware of is bleeding, which is inherent to the mechanism of action of all anticoagulant drugs. Bleeding can vary from minor (such as small bruises at the injection site) to major and potentially life-threatening (such as intracranial or retroperitoneal hemorrhage). The risk of bleeding is influenced by the dose of enoxaparin, the duration of treatment, the patient’s age and renal function, and the concurrent use of other medications that affect hemostasis.
The following frequency categories are used to classify side effects: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), rare (affects less than 1 in 1,000 people), and not known (frequency cannot be estimated from the available data).
Very Common
Affects more than 1 in 10 people
- Bleeding (minor hemorrhagic complications)
- Injection site bruising (ecchymosis)
- Elevated liver enzymes (transaminases – AST, ALT)
Common
Affects 1 in 10 to 1 in 100 people
- Injection site hematoma
- Injection site pain
- Injection site inflammation or swelling
- Thrombocytopenia (decrease in platelet count)
- Urticaria (hives)
- Skin rash
- Pruritus (itching)
- Erythema (redness)
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Major hemorrhage (gastrointestinal, retroperitoneal, intracranial)
- Injection site necrosis
- Cutaneous vasculitis
- Skin nodules at injection site (inflammatory nodules, not skin necrosis)
- Allergic reactions (systemic)
- Alopecia (hair loss)
Rare
Affects less than 1 in 1,000 people
- Heparin-induced thrombocytopenia (HIT type II)
- Anaphylactic/anaphylactoid reactions
- Spinal or epidural hematoma (in patients receiving neuraxial anesthesia)
- Skin necrosis at injection site
- Hyperkalemia (elevated potassium levels)
- Osteoporosis (with prolonged use)
Not Known
Frequency cannot be estimated from available data
- Eosinophilia (increased eosinophil count)
- Headache
- Hypersensitivity vasculitis
Elevated liver enzymes (transaminases) are very commonly observed during enoxaparin treatment and are usually transient, asymptomatic, and reversible upon discontinuation of the drug. They rarely reach clinically significant levels and do not usually necessitate treatment interruption. However, your doctor may monitor your liver function periodically, especially during prolonged treatment.
Heparin-induced thrombocytopenia (HIT) deserves special mention because, although rare, it is a serious and potentially life-threatening complication. HIT type II is an immune-mediated condition that typically develops 5 to 14 days after initiation of heparin therapy (or earlier if the patient has been previously exposed to heparin). It manifests as a significant drop in platelet count (typically more than 50% from baseline) and is paradoxically associated with an increased risk of both arterial and venous thrombosis. If HIT is suspected, enoxaparin must be discontinued immediately and an alternative non-heparin anticoagulant such as argatroban, bivalirudin, or fondaparinux should be initiated while confirmatory testing is performed.
Long-term use of heparins, including LMWHs, has been associated with a risk of osteoporosis due to effects on osteoblast and osteoclast activity. This is primarily a concern in patients receiving treatment-dose enoxaparin for extended periods (more than 3 months), such as pregnant women being treated for VTE. The risk of osteoporosis is lower with LMWHs than with unfractionated heparin. Patients on long-term enoxaparin therapy should ensure adequate calcium and vitamin D intake, and bone density monitoring may be considered in high-risk individuals.
Contact your doctor or go to the emergency department immediately if you experience: signs of major bleeding (blood in urine, blood in stool, nosebleeds that won’t stop, vomiting blood, coughing up blood, unexplained heavy bruising), signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat, severe skin rash), signs of spinal cord compression (sudden back pain, numbness or weakness in the legs, loss of bladder or bowel control), or any unexplained fall in blood pressure or feelings of dizziness and faintness.
How Should You Store Ghemaxan?
Correct storage of Ghemaxan is essential to maintain the integrity and effectiveness of the medication. The pre-filled syringes should be stored at a temperature below 25°C (77°F). Do not freeze Ghemaxan, as freezing can damage the protein structure of enoxaparin and affect its anticoagulant activity. If you suspect that the medication has been frozen, do not use it and obtain a replacement.
Keep the pre-filled syringes in their original outer packaging to protect them from light. Before use, visually inspect the solution in the syringe. Enoxaparin solution should be clear, colorless to pale yellow, and free from visible particles. Do not use the syringe if the solution appears cloudy, discolored, or contains visible particulate matter. Do not mix Ghemaxan with other injectable medications in the same syringe.
As with all medications, keep Ghemaxan out of the sight and reach of children. Do not use the medication after the expiry date stated on the carton and syringe label. The expiry date refers to the last day of the stated month. Do not dispose of medications via wastewater or household waste. Ask your pharmacist about how to dispose of medicines you no longer use, as proper disposal helps protect the environment.
What Does Ghemaxan Contain?
The active substance in Ghemaxan is enoxaparin sodium. Each pre-filled syringe contains 2,000 IU (equivalent to 20 mg) of enoxaparin sodium dissolved in 0.2 mL of solution, corresponding to a concentration of 10,000 IU (100 mg) per mL. Enoxaparin sodium is a low molecular weight heparin obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. It has an average molecular weight of approximately 4,500 daltons.
The only excipient in Ghemaxan is water for injections. The formulation does not contain preservatives, antimicrobial agents, or buffers. The simplicity of the formulation reflects the stability of enoxaparin sodium in aqueous solution and minimizes the risk of excipient-related allergic reactions.
The pre-filled syringe is made of Type I glass with a stainless-steel needle. The needle shield may contain dry natural rubber (a derivative of latex). Patients with a known allergy to latex should inform their healthcare provider before using Ghemaxan, as the latex component could potentially cause an allergic reaction in sensitive individuals. The syringe is equipped with a safety system to prevent needlestick injuries after use.
Ghemaxan is available in pre-filled syringes containing 2,000 IU (20 mg) / 0.2 mL. Other strengths of enoxaparin sodium products may be available from other manufacturers. Always verify that you are using the correct strength and brand as prescribed by your doctor.
Frequently Asked Questions About Ghemaxan
Ghemaxan contains the same active substance (enoxaparin sodium) as other enoxaparin products such as Clexane (Lovenox in the US). The key difference is that Ghemaxan is a branded enoxaparin product that may be manufactured by a different company. All enoxaparin products are derived from porcine intestinal mucosa and have the same mechanism of action, pharmacokinetic profile, and clinical indications. The EMA and other regulatory agencies require that all approved enoxaparin products meet the same quality, safety, and efficacy standards. Your pharmacist or doctor can advise on whether products can be interchanged.
Yes, many patients can learn to self-inject Ghemaxan at home after receiving proper training from a healthcare professional. The pre-filled syringe is designed for ease of use. The injection is given subcutaneously (under the skin) into the abdominal wall, alternating between the left and right sides. You should lie down for the injection, pinch a fold of skin, insert the needle vertically into the skin fold, and inject the full contents. Do not rub the injection site afterward. If you are uncomfortable with self-injection, a family member, carer, or community nurse can be trained to administer the injections.
Enoxaparin can be used for extended periods when clinically necessary, such as during pregnancy for VTE prevention or in cancer-associated thrombosis. However, long-term use (beyond 3 months) carries some additional considerations, including a potential risk of osteoporosis and injection site reactions from repeated injections. Patients on long-term therapy should ensure adequate calcium and vitamin D intake and discuss bone health monitoring with their doctor. Regular platelet count monitoring is also recommended during extended use. For most surgical and medical prophylaxis indications, treatment is short-term (1–2 weeks).
Bruising at the injection site is very common with enoxaparin and occurs in more than 1 in 10 patients. This is usually a cosmetic concern and does not indicate a serious problem. You can minimize bruising by injecting slowly, not rubbing the site after injection, alternating injection sites, and applying gentle pressure (without rubbing) for a few seconds after removing the needle. However, if you notice unusually large or spreading bruises, excessive bleeding from the injection site, hard lumps or skin color changes at the injection site, or signs of bleeding elsewhere, contact your doctor promptly.
Yes, you can travel by air while taking Ghemaxan. In fact, enoxaparin is sometimes specifically prescribed for thromboprophylaxis during long-haul flights in high-risk patients. If you need to carry pre-filled syringes during travel, keep them in their original packaging, carry a letter from your doctor explaining your medication needs, check airline regulations regarding carrying injectable medications and needles in cabin luggage, store the syringes at appropriate temperatures (below 25°C; avoid leaving them in overhead bins that may overheat or in checked luggage that may freeze), and carry enough supplies for your entire trip plus a few extra syringes as backup.
Enoxaparin can affect certain blood test results. It commonly causes a transient elevation in liver enzymes (AST and ALT), which is usually not clinically significant. It may also affect coagulation tests including aPTT (activated partial thromboplastin time), PT (prothrombin time), and anti-Xa levels. If you are transitioning to warfarin, INR monitoring should be performed before the daily enoxaparin dose (at trough level) to avoid interference. Always inform your laboratory or doctor that you are taking Ghemaxan before having blood tests.
References
- European Medicines Agency (EMA). Enoxaparin Sodium – Summary of Product Characteristics. Updated 2025. Available from: ema.europa.eu
- Konstantinides SV, Meyer G, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2020;41(4):543–603. doi:10.1093/eurheartj/ehz405
- Kearon C, Akl EA, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026
- National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline [NG89]. Updated 2024.
- Samama MM, Cohen AT, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (MEDENOX). New England Journal of Medicine. 1999;341(11):793–800.
- Antman EM, Morrow DA, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction (ExTRACT-TIMI 25). New England Journal of Medicine. 2006;354(14):1477–1488.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023. Enoxaparin listed as an essential anticoagulant.
- Bates SM, Rajasekhar A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances. 2018;2(22):3317–3359.
- British National Formulary (BNF). Enoxaparin Sodium. NICE Evidence Services. Updated 2025.
- Greinacher A. Heparin-Induced Thrombocytopenia. New England Journal of Medicine. 2015;373(3):252–261. doi:10.1056/NEJMcp1411910
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Hematology, Clinical Pharmacology, and Internal Medicine
Medical Review
iMedic Medical Review Board – Independent panel of board-certified physicians
Evidence Framework
GRADE methodology – Evidence Level 1A based on systematic reviews and randomized controlled trials
Guidelines Followed
WHO, EMA, FDA, ESC, ACCP, NICE, ASH – International clinical practice guidelines
All medical content on iMedic is independently produced with no pharmaceutical company sponsorship or commercial funding. Our editorial team follows strict evidence-based standards and declares no conflicts of interest. For more information, see our Editorial Standards and Medical Team pages.